Related Experiment Videos
Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized
F H Bloomfield1, D B Knight, J E Harding
1Department of Pediatrics, National Women's Hospital, Auckland, New Zealand.
Insights
A pulsed course of dexamethasone in preterm infants showed fewer side effects than a long course but was less effective in preventing chronic lung disease. This finding impacts treatment strategies for premature infants requiring respiratory support.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Preterm infants are at high risk for chronic lung disease of prematurity (CLD).
- Dexamethasone is used to manage CLD, but long courses have significant side effects.
- Pulsed dexamethasone regimens are explored as a potentially safer alternative.
Purpose of the Study:
- To compare the efficacy of a pulsed dexamethasone course versus a 42-day reducing course on linear growth in preterm infants.
- To evaluate the safety profile and effectiveness in preventing CLD.
Main Methods:
- Randomized trial involving 40 preterm infants (< or =1,250 g birth weight) requiring mechanical ventilation.
- Two groups: immediate 3-day pulse dexamethasone vs. 42-day reducing course if mechanical ventilation and oxygen were still needed at 14 days.
- Primary outcome: linear growth at 36 weeks' postmenstrual age (PMA) via knemometry.
Main Results:
- No significant difference in linear growth (lower leg length) at 36 weeks' PMA between groups.
- Pulsed dexamethasone group had fewer adverse effects: lower blood pressure, less myocardial hypertrophy, and less adrenal suppression.
- However, the pulsed group required more supplemental oxygen at 28 days' postnatal age and 36 weeks' PMA.
Conclusions:
- Pulsed dexamethasone courses in preterm infants at risk for CLD have a better safety profile with fewer side effects compared to long courses.
- Despite a better safety profile, pulsed dexamethasone may be less effective in preventing or managing chronic lung disease.
- Further research is needed to optimize dexamethasone treatment for preterm infants to balance efficacy and safety.
Objective:
We hypothesized that a pulsed course of dexamethasone would result in better linear growth than a 42-day reducing course in preterm infants at risk for chronic lung disease of prematurity.
Study Design:
Forty infants with a birth weight of < or =1,250 g who required mechanical ventilation at 7 days of age were randomly assigned to a repeatable 3-day pulse course of dexamethasone commencing immediately or a 42-day (long) course commencing at 14 days of age if they still required mechanical ventilation and supplemental oxygen. The primary outcome measure was linear growth at 36 weeks' postmenstrual age measured by knemometry.
Results:
There was no difference in lower leg length at 36 weeks' postmenstrual age. Infants receiving the pulse course had lower rises in blood pressure, less myocardial hypertrophy, and less adrenal suppression. However, more infants required supplemental oxygen at 28 days' postnatal age (14/18 vs 8/21, P < .05) and 36 weeks' PMA (8/16 vs 5/20, P = .12).
Conclusion:
In preterm infants at risk for chronic lung disease, a pulsed course of dexamethasone has fewer side effects than a long course but may be less effective at preventing chronic lung disease.